Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?

Eli Lilly's stock has surged above $1,000, driven primarily by its dominant position in the weight loss drug market. With the stock trading at these elevated levels, analysts speculate whether the company might announce a stock split to make shares more accessible to investors. While Lilly hasn't executed a stock split since 1997, a move could broaden its investor base and signal management confidence in future growth, particularly given recent launches like Foundayo and strong trial results for retatrutide.